A researcher holds a vial of an experimental Ebola vaccine in Oxford, England, Sept. 17, 2014. Researchers say an experimental Ebola vaccine has caused no serious side effects and produced an immune response in all 20 healthy volunteers who received it in an early-stage clinical trial.
The New England Journal of Medicine said Wednesday that scientists will continue to follow the volunteers for another 48 weeks in the study that began on September 2.
The aim of the trial is to determine the safety of the vaccine, produced by British firm GlaxoSmithKline.
The news comes a day after the World Health Organization said the ongoing Ebola outbreak in West Africa has killed nearly 5,700 people out of some 16,000 cases.
The chairman of Global Vaccines at GlaxoSmithKline, Dr. Moncef Slaoui, said the company was encouraged by the positive first trial results, but added, “It’s important to remember that these data are the first piece in the jigsaw.” FILE – Dr. Anthony Fauci testifies before the House Foreign Affairs subcommittee on Africa, Global Health, Global Human Rights, and International Organizations. Dr. Anthony Fauci, the director of the U.S. National Institute of Allergy and Infectious Diseases (NIAID), said “The safety profile is […]